Synthesis and conformational analysis of tetrahydroisoquinoline- and piperidine-fused 1,3,4,2-oxadiazaphosphinanes, new ring systems
作者:Zita Zalán、Tamás A. Martinek、László Lázár、Reijo Sillanpää、Ferenc Fülöp
DOI:10.1016/j.tet.2006.01.018
日期:2006.3
representatives of these ringsystems, were prepared. NMR and X-ray diffraction studies revealed that, independently of the P-substituent and the relative configuration of the phosphorus atom, 13, 14, 17 and 18 could be characterized by trans-connected hetero rings and the chair conformation of the 1,3,4,2-oxadiazaphosphinane moiety, while the stereochemistry of the connection of the hetero rings in the 1,3,4
通过四氢异喹啉和哌啶-1,2-二肼基醇与苯基膦酰二氯和苯基二氯,环化P的1,6,7,11b四氢-4- -epimeric非对映体ħ -oxadiazaphosphino -1,3,4,2 [5,4 -一个]异喹啉-3-氧化物(13和14),1,6,11,11a四氢-4- ħ -1,3,4,2-oxadiazaphosphino并[4,5- b ]异喹啉-3-氧化物(15和16)和1,6,7,8,9,9a-hexahydro-4 H-吡啶[1,2- d ] [1,3,4,2]草二氮膦3氧化物(17和18),这些环系统的第一批代表已经准备好了。NMR和X射线衍射研究显示,独立于P -取代和磷原子的相对构型,13,14,17和18可以通过反式连接的杂环和1,3的椅式构象的特征在于1,4,2-氧杂二氮杂膦烷部分,而线性地稠合于四氢异喹啉(15和16)的1,3,4,2-氧杂二氮杂膦杂环中的杂环连接的
INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES
申请人:Biotie Therapies Corp.
公开号:EP1301495A2
公开(公告)日:2003-04-16
[EN] INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES<br/>[FR] INHIBITEUR D'AMINE OXYDASES CONTENANT DU CUIVRE
申请人:BIOTIE THERAPIES CORP
公开号:WO2002002541A2
公开(公告)日:2002-01-10
The present invention is directed to 1,3,4-oxadiazine compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to abberations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula (I): or a tautomer, isomer, hydrazino alcohol degradation product, or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R?1, R2, R3, R4, R5,R6, R7, and R8¿ are as defined her ein.